CD19 and non-Hodgkin lymphoma: Interestingly, our CD19 CAR T cells combined with DAC-based lymphodepletion demonstrated high efficacy against multiple types of NHL, comparing favorably to the response rates observed with FDA-approved products such as axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel.24